PRF Technologies (PRFX) Other Non-Current Assets (2019 - 2020)
PRF Technologies (PRFX) posted quarterly Other Non-Current Assets of $274000.0 for Q2 2020, up 42.71% on a QoQ basis from $192000.0 in Q4 2019.
PRF Technologies (PRFX) Other Non-Current Assets (2019 - 2020) Analysis & Trends
PRF Technologies (PRFX) has reported Other Non-Current Assets for 2 consecutive years, with $274000.0 the latest figure, recorded in Q2 2020.
- Quarterly Other Non-Current Assets changed N/A year-over-year to $274000.0 in Q2 2020, while the trailing twelve-month figure through Jun 2020 was $274000.0 (changed N/A YoY) and the FY2019 annual result came in at $192000.0, changed N/A from the prior year.
- Other Non-Current Assets rose to $274000.0 in Q2 2020 per PRFX's latest filing, from $192000.0 in the prior quarter.
- Over the last five years, Other Non-Current Assets for PRFX reached as high as $274000.0 in Q2 2020 and fell as low as $192000.0 in Q4 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 49.22 Mn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 1.79 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 351.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 491.06 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 233.20 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 1.11 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 73.60 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 295.00 Mn |
| 10 | PRF Technologies | 745,168.93 | 451,168.93 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2020 | 274,000.00 |
| Dec 31, 2019 | 192,000.00 |